Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment

DADI Trial Group, Japan

Research output: Contribution to journalArticlepeer-review

43 Citations (Scopus)

Fingerprint Dive into the research topics of 'Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment'. Together they form a unique fingerprint.

Medicine & Life Sciences